Method of treating cancer based on identifying mutations in the extracellular domain III of epidermal growth factor receptor gene
US11015225B2 · kind B2 · utility
0Cited by
1References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 30, 2014 |
| Grant date | May 25, 2021 |
| Priority date | — |
| Expiry date | Dec 30, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to new identified mutations in the epidermal growth factor receptor gene, leading to amino acidic changes which highly correlate with the resistance to a therapy regimen comprising cetuximab. The invention includes peptide sequences and primers to detect the mutations, as well as kits for predicting the response of a subject to a therapy regime comprising cetuximab. In particular, the invention is useful in the therapy regimen applicable to metastasic colorectal cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.